Personalized mRNA cancer vaccines, like Moderna and Merck's mRNA-4157, have shown promising results in Phase 2 trials for melanoma, reducing recurrence or death by 44% when combined with Keytruda. BioNTech also has a diversified oncology pipeline with over 20 clinical programs, including mRNA cancer immunotherapies for various solid tumors.